Immunotherapy has transformed the treatment of solid organ cancers, rapidly becoming a first line therapy with transformative durable response. While immunotherapies have favorable toxicity profiles compared to traditional chemotherapies, immunotherapy is associated with the development of immune-related adverse events (irAEs), an autoimmune condition incited by activation of the immune system.

20% to 60% of patients receiving immune checkpoint inhibitors (ICIs) will experience severe irAEs that can limit therapeutic continuation of treatment. Severe iRAEs that occur in major organs can be life-threatening, and these adverse events have profound influence on the overall outcomes associated with checkpoint inhibitor drugs.

There is a pressing need to identify reliable biomarkers that further elucidate how immunotherapies modify existing immune responses to disease, predict toxicities, and help to guide the treatment and management of at-risk patients.

Download this case study to learn how Sapient discovered a robust, specific circulating biomarker that identifies individuals who are at risk for severe autoimmune events in the setting of ICI.

Discovery of Biomarker to Predict Immunotherapy Related Autoimmunity

Immunotherapy has transformed the treatment of solid organ cancers, rapidly becoming a first line therapy with transformative durable response. While immunotherapies have favorable toxicity profiles compared to traditional chemotherapies, immunotherapy is associated with the development of immune-related adverse events (irAEs), an autoimmune condition incited by activation of the immune system. Read More